PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33405090-0	2021	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma.	AZD 6244	18-29	mitogen-activated protein kinase kinase 2	Homo sapiens	70-74	
24938562-2	2014	OBJECTIVE: To assess the efficacy of selumetinib, a selective, non-adenosine triphosphate competitive inhibitor of MEK1 and MEK2, in uveal melanoma.	AZD 6244	37-48	mitogen-activated protein kinase kinase 2	Homo sapiens	124-128	
32880495-5	2020	EXPERT OPINION: Selumetinib is an oral selective allosteric inhibitor of MEK1 and MEK2 kinases.	AZD 6244	16-27	mitogen-activated protein kinase kinase 2	Homo sapiens	82-86	
27100819-11	2016	While there has been limited success in inhibiting the protein directly, phase 2 and phase 3 clinical trials have demonstrated success in inhibiting downstream effectors, specifically MEK1 and/or MEK2 with selumetinib and trametinib (albeit with poor tolerability).	AZD 6244	206-217	mitogen-activated protein kinase kinase 2	Homo sapiens	196-200	
33683166-11	2021	Selumetinib is an inhibitor of MEK1 and MEK2 proteins, which play an important role in the MAPK signaling pathway related to tumor growth.	AZD 6244	0-11	mitogen-activated protein kinase kinase 2	Homo sapiens	40-44	
25278770-3	2014	Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, which are essential downstream molecules in the MAPK pathway.	AZD 6244	0-11	mitogen-activated protein kinase kinase 2	Homo sapiens	60-64	
22394161-4	2012	Selumetinib is an orally available, selective non-ATP-competitive MEK1 and MEK2 inhibitor.	AZD 6244	0-11	mitogen-activated protein kinase kinase 2	Homo sapiens	75-79	
23406027-4	2013	METHODS: We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 inhibitor selumetinib (AZD6244, ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer.	AZD 6244	94-105	mitogen-activated protein kinase kinase 2	Homo sapiens	79-83	
23406027-4	2013	METHODS: We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 inhibitor selumetinib (AZD6244, ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer.	AZD 6244	107-114	mitogen-activated protein kinase kinase 2	Homo sapiens	79-83	
23406027-4	2013	METHODS: We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 inhibitor selumetinib (AZD6244, ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer.	AZD 6244	116-127	mitogen-activated protein kinase kinase 2	Homo sapiens	79-83	
23200175-2	2013	Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers.	AZD 6244	0-11	mitogen-activated protein kinase kinase 2	Homo sapiens	36-40